Kincell Bio is a contract development and manufacturing organization (CDMO) that specializes in cell therapy development and manufacturing. The company is dedicated to accelerating early-stage biotech innovations by providing tailored manufacturing solutions. Kincell Bio supports cell therapy innovators in advancing their products from early clinical supply through to commercial launch.

Emerging as a spinout from Inceptor Bio, Kincell Bio operates primarily from facilities in Gainesville, Florida, with plans for expansion into other biotech hubs like Research Triangle Park and Boston. The company offers a wide range of CDMO services, including analytical development, process development, CMC consulting, and early-stage Good Manufacturing Practice (GMP) manufacturing. Kincell Bio focuses on immune cell therapies, such as CAR-T, CAR-NK, and CAR-M programs, and plans to enhance its capabilities with in-house mRNA development and additional GMP manufacturing capacity.

Kincell Bio targets cell therapy innovators and biotech companies that require expert support to transition their products from research to clinical and commercial stages. The company emphasizes scientific integrity and a collaborative approach, positioning itself as an extension of its clients' teams.